Drug intelligence / Profile preview

LBM801

Development stage: Unknown
Lead developer: Shanghai Likangrui Biology Engineering
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intraarticular

Overview

LBM801 is an umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy developed by Shanghai Bosaimi Biotechnology and Shanghai Likangrui Bioengineering. It is designed for the treatment of knee osteoarthritis, a degenerative joint disease characterized by cartilage loss and inflammation. Administered via a single intra-articular injection, LBM801 aims to leverage the immunomodulatory, anti-inflammatory, and potential regenerative properties of MSCs to alleviate pain, improve joint function, and slow disease progression. The product is currently being evaluated in a Phase I clinical trial in China to determine its safety, tolerability, and preliminary efficacy across escalating doses.

Beyond the preview

Go deeper on LBM801.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LBM801.

Explore the full profile